Genome editing for hereditary angioedema: A landmark trial and important unanswered questions
Mauro Cancian1, Maurizio Margaglione2
1Departmental Division of Allergy, Department of Systems Medicine, University Hospital of Padua, Padua, Italy.
Abstract:
Hereditary angioedema is a bradykinin-mediated genetic disorder increasingly controlled with effective long-term prophylaxis. In a phase 3 trial, a single dose of lonvoguran ziclumeran, an in vivo CRISPR-Cas9 therapy targeting KLKB1, significantly reduced attack rates. This approach represents a highly promising therapeutic strategy for HAE. However, it also raises important questions that require further investigation.
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
What is Genetic Engineering?
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
CRISPR
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
